Skip to content
Spiritual Quotes – Lifestyle
Author:
Oryzon Genomics, S.A.
ORYZON Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026
July 27, 2026
ORYZON Announces U.S. Patent Grant for Vafidemstat in Borderline Personality Disorder (BPD)
July 8, 2026
ORYZON Raises €12 Million and Signs a Financing Agreement with COFIDES to Strengthen its Balance Sheet and Accelerate its Clinical Programs
July 1, 2026
ORYZON Presents Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia (AML) at European Hematology Association (EHA) 2026 Annual Congress
June 11, 2026
ORYZON Initiates Patient Enrollment in IDEAL Phase II Trial of Iadademstat in Essential Thrombocythemia
June 2, 2026
ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31st, 2026
May 14, 2026
ORYZON to Present Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia at EHA 2026
May 13, 2026
ORYZON to Participate in Upcoming Events in May and June
April 29, 2026
ORYZON Strengthens Vafidemstat Patent Portfolio With U.S. Notice of Allowance
March 25, 2026
ORYZON Announces U.S. Patent Grant Covering Iadademstat Combinations with Venetoclax
March 23, 2026
1
2
Next Page
→